CD19 and acute lymphoblastic leukemia: Imai et al. showed that in vivo anti-CD19 chimeric receptors containing the 4-1BB signal transduction domain had powerful antileukemic activity, destroying CD19+ acute lymphoblastic leukemia (ALL) cell lines in an in vivo microenvironment [33].